Trial Search Results

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Comprehensive Cancer Network


  • Procedure: FDG PET CT
  • Procedure: DCE MRI
  • Drug: F-18 Fluoro-deoxi-glucose
  • Drug: Gadolinium-DTPA
  • Drug: Sunitinib




Inclusion Criteria:- Measurable disease by RECIST criteria

   - Pathologic diagnosis of renal cell cancer

   - Advanced (stage IV) renal cell cancer

   - Karnofsky performance status of (KPS>70)

   - Consent to participate in the clinical trial Exclusion Criteria:- Patients who cannot
   complete a PET/CT scan.

   - Pregnant women.

   - Healthy volunteers.

   - Patients participating in other research protocols will be excluded from this study.

   - Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications for

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrew Quon